AUTHOR=Yan Hao-Zhen , Huang Zhi-Hao , Guo Xu-Guang , Peng Ting-Ting , Yang Li-Li , Liu Chong-Wen , Ou-Yang Shi 

TITLE=A Study on Pregenomic RNA and Factors Related to Hepatitis B Virus Infection Based on Real World

JOURNAL=Frontiers in Public Health

VOLUME=Volume 10 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.856103

DOI=10.3389/fpubh.2022.856103

ISSN=2296-2565

ABSTRACT=Objective: To study the influencing factors of pgRNA and its change magnitude based on real world.
Methods: A total of 421 patients that were tested for pgRNA were selected. According to the baseline data, the subjects were divided into negative and positive group. Chi-square test and logistic regression were used to analyze the influencing factors of pgRNA status. Based on the follow-up data, rank-sum test and linear regression were used to analyze the influencing factors of pgRNA change magnitude.
Results: 153 (36.3%) of the 421 subjects were pgRNA negative and 268 (63.7%) were pgRNA positive. Logistic regression analysis showed that positive HBV DNA (OR: 40.51), positive HBeAg (OR: 66.24), tenofovir treatment (OR: 23.47) and entecavir treatment (OR: 14.90) were independent risk factors for positive pgRNA. Univariate linear regression showed that pgRNA change magnitude of patients treated with entecavir was higher than that of patients treated with tenofovir. Multivariate linear regression showed that age was an independent factor influencing pgRNA change magnitude.
Conclusions: The pgRNA of patients that were young, female, HBV DNA-positive, high-HBsAg, HBeAg-positive is higher than the detection line. HBV DNA, HBeAg are independent risk factors of positive pgRNA. Different antiviral regimens and disease stages have significantly different effects on pgRNA status. There was a significant correlation between pgRNA and FIB-4, suggesting that pgRNA is related to liver fibrosis. The decrease in pgRNA was greater in young patients than in non-young patients. The decrease in pgRNA was greater in patients treated with tenofovir than in patients treated with entecavir.